《大行報告》瑞銀首予海吉亞醫療(06078.HK)「買入」評級 目標價62元
瑞銀發表報告,首予海吉亞醫療(06078.HK)「買入」評級,目標價62元。
報告指,海吉亞醫療是內地領先的腫瘤醫院集團,經營和管理著12間腫瘤醫院。該行偏好其強勁的醫院營運能力和規模可擴展性。受惠於未被滿足的醫療需求,特別是在偏遠城市,根據海吉亞醫療的擴張計劃,該行預計2021至2024年間,公司將分別實現30%的收入年複合增長率,以及27%的淨利潤年複合增長率。按公司指引,在每年潛在收購一至兩間醫院情況下,該行予其預測將有上行空間。
該行予其2022至2024年各年每股盈測分別1.01元、1.23元及1.51元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.